KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $564.5 million.

  • Royalty Pharma's Shares Outstanding (Diluted Average) fell 499.12% to $564.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $564.5 million, marking a year-over-year decrease of 499.12%. This contributed to the annual value of $564.5 million for FY2025, which is 499.12% down from last year.
  • Royalty Pharma's Shares Outstanding (Diluted Average) amounted to $564.5 million in Q4 2025, which was down 499.12% from $566.8 million recorded in Q3 2025.
  • Royalty Pharma's 5-year Shares Outstanding (Diluted Average) high stood at $607.3 million for Q1 2023, and its period low was $414.8 million during Q4 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $579.1 million, with a median of $600.2 million in 2023.
  • Per our database at Business Quant, Royalty Pharma's Shares Outstanding (Diluted Average) surged by 7152.47% in 2021 and then crashed by 499.12% in 2025.
  • Over the past 5 years, Royalty Pharma's Shares Outstanding (Diluted Average) (Quarter) stood at $414.8 million in 2021, then rose by 5.59% to $438.0 million in 2022, then surged by 37.66% to $602.9 million in 2023, then dropped by 1.46% to $594.1 million in 2024, then decreased by 4.99% to $564.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $564.5 million for Q4 2025, versus $566.8 million for Q3 2025 and $570.2 million for Q2 2025.